Cargando…

The Significance of Information Posted on the U.S. Food and Drug Administration’s Website

Detalles Bibliográficos
Autores principales:	Cook, G. Elliott, Madden, Michael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2013
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438041/ https://www.ncbi.nlm.nih.gov/pubmed/23383703 http://dx.doi.org/10.18553/jmcp.2013.19.1.72

Ejemplares similares

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

Exposure to untrustworthy websites in the 2016 U.S. election
por: Guess, Andrew M., et al.
Publicado: (2020)

Vaccines, pharmaceutical products, and bioterrorism: challenges for the U.S. Food and Drug Administration.
por: Zoon, K C
Publicado: (1999)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
por: Lex, Joe
Publicado: (2016)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Assessment of Public Opinion on Transparency at the US Food and Drug Administration
por: Azad, Tej D., et al.
Publicado: (2022)

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration
por: Sullivan, Helen W., et al.
Publicado: (2016)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

HIV-, HBV-, and HCV-Related Information on U.S. Fertility Clinic Websites: A Content Analysis
por: Kelly-Hedrick, Margot, et al.
Publicado: (2020)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
por: Kuehn, Carrie M.
Publicado: (2019)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
por: Hirshberg, Boaz, et al.
Publicado: (2011)

Assessment of Spanish Translation of Websites at Top-Ranked US Hospitals
por: Honeycutt, Christopher Cole, et al.
Publicado: (2021)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Accessibility of State and Territory Public Health Department Website Information on COVID-19 Outpatient Treatments in the US
por: Eckert, Cody, et al.
Publicado: (2023)

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
por: Abulwerdi, Gelareh A., et al.
Publicado: (2023)

Priority-based assessment of food additives database of the U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition.
por: Benz, R D, et al.
Publicado: (1991)

Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization
por: Anderson, Timothy S., et al.
Publicado: (2022)

U.S. Food and Drug Administration-Certified Food Dyes as Organocatalysts in the Visible Light-Promoted Chlorination of Aromatics and Heteroaromatics
por: Rogers, David A., et al.
Publicado: (2020)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Prevalence of Third-Party Data Tracking by US Hospital Websites
por: Niforatos, Joshua D., et al.
Publicado: (2021)

Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
por: Putzke, Joerg, et al.
Publicado: (2021)

DOE's Office of Science launches Website for U.S. role at Large Hadron Collider
Publicado: (2007)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
por: Learned, Christine, et al.
Publicado: (2022)

US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera M., et al.
Publicado: (2023)

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
por: Lipner, Shari R., et al.
Publicado: (2020)

ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research.
por: Tong, Weida, et al.
Publicado: (2003)

U.S. Food and Drug Administration perspective of the inclusion of effects of low-level exposures in safety and risk assessment.
por: Gaylor, D W, et al.
Publicado: (1998)

The U.S. Food and Drug Administration Risk Assessment on Lead in Women’s and Children’s Vitamins Is Based on Outdated Assumptions
por: Miodovnik, Amir, et al.
Publicado: (2009)

Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications
por: Chua, Kao-Ping, et al.
Publicado: (2021)

Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system
por: Zhou, Yangzhong, et al.
Publicado: (2021)

Cyberpharmacies and the role of the US Food And Drug Administration
por: Henney, Jane E
Publicado: (2001)

The US Food and Drug Administration’s Intersection with Dermatology
por: Luke, Markham C.
Publicado: (2022)

Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs
por: Shahid, Izza, et al.
Publicado: (2022)

Use of Clinical Outcome Assessments in New Drug Approvals by the US Food and Drug Administration Divisions of Neurology I and II
por: Schein, Yvette, et al.
Publicado: (2022)

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey
por: DiStefano, Michael J., et al.
Publicado: (2022)

Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015
por: MacGregor, Andrea, et al.
Publicado: (2020)

Physical Activity Programming Advertised on Websites of U.S. Islamic Centers: A Content Analysis
por: Kahan, David
Publicado: (2018)

U.S. medical organizations and climate change advocacy: a review of public facing websites
por: Bush, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8ng1of23pc9l79qop9go80305t